June Disclosure Window Puts Transfers of Value Back in Focus

June remains one of the most important months in the European transparency calendar, as pharmaceutical companies prepare and publish annual disclosures of Transfers of Value to healthcare professionals and healthcare organisations.

Under the EFPIA transparency framework, member companies disclose payments and other Transfers of Value made to HCPs and HCOs. The disclosure framework was created to increase transparency around industry relationships with healthcare professionals, healthcare organisations, and patient organisations. (EFPIA)

The June window is particularly important because many companies publish or refresh their annual European disclosures around this period. Several companies also maintain public transparency pages and country-level disclosure reports as part of their EFPIA and local transparency commitments. (Lilly)

For compliance teams, the June publication period is not simply a communications exercise. It is the point where data quality, consent handling, HCP/HCO classification, cross-border spend, grants, sponsorships, and methodology notes become visible externally.

In Italy, this annual disclosure cycle also sits alongside broader expectations around transparency, ethics, and the coming operationalisation of national Sunshine reporting. That makes June a useful moment for companies to review whether their ToV data processes are consistent, defensible, and ready for increased scrutiny.